IMU

IMUGENE FPO [IMU]
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Healthcare · ASX Small Cap
$0.0940 +2.2%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when IMU triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IMU — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Critical cash runway (0.9 quarters)
  • Moderate P/S ratio (11.6x)
  • Revenue in sharp decline (-36%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (1% of range)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 62% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (3.40%/day)
  • Altman Z-Score distress zone (1.79 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 11d (+3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -36% — the top line is shrinking
Ask Scout AI about IMU
"What's driving IMU today?" "How does IMU compare to peers?" "Key risks for IMU?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notification of cessation of securities - IMU
NONE Notice of Extraordinary General Meeting/Proxy Form
NONE Cleansing Notice

Recent ASX Announcements

2026-07-17 Notification of cessation of securities - IMU
2026-07-16 Notice of Extraordinary General Meeting/Proxy Form
2026-07-13 Cleansing Notice
2026-07-13 Application for quotation of securities - IMU
2026-07-09 Application for quotation of securities - IMU

Key Metrics

$45.8M
Market Cap
4.8M
Avg Volume
0.8x
Vol Ratio
$0.09 — $0.46
52-Week Range
0.8%
Short Interest
N/A
Cash Runway
-111.3%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 56%
LLeader vs LaggardlaggardRS: -9
IInstitutional SponsorshipweakInst: 4%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:IMU vs IDTIMU vs ADRIMU vs LDX
Scout Pro — Deeper Analysis for IMU
Try Pro free for 30 days
Share this analysis

Track IMU and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required